Recursion Pharmaceuticals... (RXRX)
Recursion Pharmaceuticals Statistics
Share Statistics
Recursion Pharmaceuticals has 399.66M shares outstanding. The number of shares has increased by 71.69% in one year.
| 399.66M |
| 71.69% |
| 2.96% |
| 99.99% |
| 310.78M |
| 745,904 |
| 3.58% |
Short Selling Information
The latest short interest is 104.22M, so 25.64% of the outstanding shares have been sold short.
| 104.22M |
| 25.64% |
| 27.66% |
| 4.73 |
Valuation Ratios
The PE ratio is -4 and the forward PE ratio is -3.74. Recursion Pharmaceuticals's PEG ratio is -0.57.
| -4 |
| -3.74 |
| 31.5 |
| 11.3 |
| 1.79 |
| -4.97 |
| -0.57 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Recursion Pharmaceuticals.
| n/a |
| n/a |
| n/a |
| n/a |
Financial Position
The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.1.
| 3.81 |
| 3.81 |
| 0.1 |
| -0.25 |
| -0.29 |
| -304.71 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| n/a |
| n/a |
| n/a |
| $73,548.75 |
| $-579,576.25 |
| 800 |
| 0.04 |
| n/a |
Taxes
| -1.13M |
| 0.24% |
Stock Price Statistics
The stock price has increased by -35.49% in the last 52 weeks. The beta is 0.83, so Recursion Pharmaceuticals's price volatility has been higher than the market average.
| 0.83 |
| -35.49% |
| 4.89 |
| 6.47 |
| 61.42 |
| 20,830,187 |
Income Statement
In the last 12 months, Recursion Pharmaceuticals had revenue of 58.84M and earned -463.66M in profits. Earnings per share was -1.69.
| 58.84M |
| 13.6M |
| -479M |
| -463.66M |
| -426.72M |
| -463.22M |
| -1.69 |
Balance Sheet
The company has 594.35M in cash and 108.49M in debt, giving a net cash position of 485.86M.
| 594.35M |
| 108.49M |
| 485.86M |
| -1.43B |
| 1.31B |
| 442.16M |
Cash Flow
In the last 12 months, operating cash flow was -359.17M and capital expenditures -13.7M, giving a free cash flow of -372.87M.
| -359.17M |
| -13.7M |
| -372.87M |
| -1.36 |
Margins
Gross margin is 23.12%, with operating and profit margins of -814.09% and -788.02%.
| 23.12% |
| -814.09% |
| -789.93% |
| -788.02% |
| -725.24% |
| -814.09% |
| -633.71% |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Analyst Forecast
The average price target for RXRX is $8, which is 45.7% higher than the current price. The consensus rating is "Hold".
| $8 |
| 45.7% |
| Hold |
| 5 |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| n/a |
| n/a |
| n/a |
Scores
| 0.15 |
| 1 |